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Abstract
Introduction: The incidence of Kaposi sarcoma (KS) has increased dramatically among women in sub-Saharan Africa since the
onset of the HIVpandemic, but data on KS disease in women are limited.To identify gender-relateddifferences in KS presentation
and outcomes, we evaluated the clinical manifestations and response in men and women with AIDS-associated KS in Uganda.
Methods and Findings: HIV-infected adults with KS attending the Infectious Diseases Institute (IDI) and Uganda Cancer
Institute (UCI) in Kampala, Uganda between 2004 and 2006 were included in a retrospective cohort. Evaluation of KS
presentation was based on the clinical features described at the initial KS visit. Response was evaluated as the time to
‘‘improvement’’, as defined by any decrease in lesion size, lesion number, or edema. The cohort consisted of 197 adults with
HIV and KS: 55% (108/197) were women. At presentation, the median CD4 T-cell count was significantly lower in women
(58 cells/mm
3; IQR 11–156 cells/mm
3) than men (124 cells/mm
3; IQR 22–254 cells/mm
3) (p=0.02). Women were more likely
than men to present with lesions of the face (OR 2.8, 95% CI, 1.4, 5.7; p=0.005) and hard palate (OR 2.0, 95% CI, 1.1, 3.7;
p=0.02), and were less likely than men to have lower extremity lesions (OR 0.54, 95% CI, 0.3, 0.99; p=0.05). Women were
less likely than men to demonstrate clinical improvement (HR=0.52, CI 0.31, 0.88; p=0.01) in multivariate analysis.
Conclusions: The clinical presentation and response of KS differs between men and women in Uganda. These data suggest
that gender affects the pathophysiology of KS, which may have implications for the prevention, diagnosis, and treatment of
KS in both men and women. Prospective studies are needed to identify predictors of response and evaluate efficacy of
treatment in women with KS, particularly in Africa where the disease burden is greatest.
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Introduction
Kaposi sarcoma (KS) is the most common HIV-related
malignancy worldwide and the most frequently diagnosed cancer
in several African countries. Previously recognized as a disease
almost exclusively of men, the incidence of KS has increased
exponentially in women since the beginning of the HIV pandemic,
most dramatically among women in sub-Saharan Africa. Prior to
the onset of HIV, women accounted for 5–10% of KS cases but
now account for up to 40% of incident KS in many African
countries [1–5]. In Uganda, which has one of the highest rates of
KS in the world, the incidence of KS has become nearly equal in
men and women, and it has surpassed cervical cancer as the most
common female malignancy in the entire population [6].
Despite the increasing burden of disease, little is known about KS
in women. Because KS has historically been a male disease and cases
in HIV-infected women in the developed world are rare, studies of
KS have been predominantly in men [7]. A few reports suggest that
epidemic (or HIV-associated) KS in women is associated with more
severedisease and worseprognosis compared to men[8–11], butdata
on gender differences in KS are limited, particularly in regions of the
world with high burdens of KS. The two published studies describing
KS presentation in African women found that they are younger at
time of presentation, have more extensive cutaneous disease, and
more systemic symptoms than men [12,13]. However, neither study
evaluatedclinicaloutcomes,whichcouldhaveimportantimplications
for the management of KS in African women. We hypothesized that
the clinical presentation and outcomes of KS differ by gender in
Uganda; to address our hypothesis, we conducted a retrospective
s t u d yo fm e na n dw o m e nw i t hH I V - a s s o c i a t e dK S .
Methods
Study Population
We evaluated a cohort of patients with HIV-associated KS who
had received HIV care at the Infectious Diseases Institute (IDI) in
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2006. Patients were eligible for the study if they had histologically
or clinically diagnosed KS, had HIV infection, and were $18
years of age at the time of KS diagnosis. Only those patients with
at least one follow-up clinic visit after their initial KS diagnosis
were included in analysis of clinical response.
Data Collection
Data were obtained by chart review using a standardized case
report form. Data were abstracted from both IDI charts and from
records at the Uganda Cancer Institute (UCI) in Kampala, where
patients from the IDI are referred for cancer care. We linked
patient records from the IDI and UCI to compile demographic
data and descriptions of KS clinical presentation and outcomes
from both institutions.
Definitions
KS presentation was based on variables described at the initial
KS visit at the IDI and UCI. Demographic variables included
patient age at KS diagnosis and gender. Baseline clinical
characteristics included body mass index (BMI), Karnofsky score,
and CD4 T-cell count. BMI was categorized as underweight if
BMI,18.5 kg/m
2 and normal weight if BMI $18.5 kg/m
2 [14].
The Karnofsky score, a measure of performance status, was
categorized as a score $70 and ,70 to distinguish those who can
and cannot care for themselves without assistance [15]. The CD4
T-cell count obtained closest to the KS diagnosis and within 6
months of diagnosis was used in the analyses. CD4 count was
evaluated as both a continuous and dichotomous variable,
categorized as ,200 and $200 cell/ml. Tumor stage was defined
according to the AIDS Clinical Trials Group (ACTG) classifica-
tion as T1 if there was visceral involvement, tumor-associated
edema or ulcerations, or oral involvement beyond the hard palate;
otherwise, stage was classified as T0 [16]. Lesion morphotype was
classified as ‘‘macular’’, ‘‘nodular’’ or ‘‘fungating’’ if explicitly
described as such in the medical record. Anatomic sites were
categorized as face/neck, hard palate, oral (outside hard palate),
trunk, upper extremities, lower extremities, and genitals.
For evaluation of response, ‘‘improvement’’ was defined as any
decrease in lesion size, lesion number, or lesion-associated edema
noted in the clinical charts, to reflect AIDS Clinical Trials Group
(ACTG) KS response criteria [17]. ‘‘Time to improvement’’ was
calculated from the date of KS diagnosis to the date of the first
clinic visit that the patient met criteria for ‘‘improvement’’.
Statistical Analysis
To explore our hypothesis that KS clinical presentation differs
between men and women, we evaluated patient characteristics at
KS diagnosis, including age, BMI, Karnofsky score, CD4 count,
tumor stage, lesion morphotype, lesion location, lesion number,
and tumor-associated edema. Differences in KS presentation were
determined using Pearson’s chi-square test and logistic regression.
To evaluate our hypothesis that clinical outcomes differ by
gender, we estimated the cumulative incidence of disease impro-
vement using Kaplan-Meier survival analysis. Events were
censored at the date of the last visit, date of death, at 180 days,
or at the end of the study period (December 31, 2006), whichever
came first. Observations were censored at 180 days (6 months) to
focus on gender differences in the period immediately following
presentation and to limit the potential effect of patients with longer
follow-up on the overall risk estimates. We fitted a Cox propor-
tional hazard model for time to improvement for the same
demographic and clinical covariates assessed in KS presentation.
Univariate predictors with a two-sided p-value #0.2 were included
in the multivariate model, and backward elimination was applied
to obtain a final model; two-sided p-values #0.05 were considered
significant. Because this retrospective study includes a fixed sample
size, associations not demonstrated should not be viewed as
definitive lack of association. To test our hypotheses about gender
differences in KS with our cohort sample size, we have 80% power
to recognize a 53% difference in the frequency of clinical chara-
cteristics at presentation and a 59% difference in the hazard of
improvement between men and women with a significance level of
0.05. All statistical calculations were performed using Stata 11.0
(Statacorp, College Station, TX).
Ethics Statement
The Institutional Review Boards at Makerere University,
Mulago Hospital, the Uganda National Council for Science and
Technology, and the University of Washington approved the study
procedures. The Institutional Review Boards determined that this
retrospective study met requirements for a waiver of consent and
authorization.
Results
Characteristics of Study Cohort
We identified 197 adults who attended the IDI with a diagnosis
of HIV-associated KS between January 2004 and December 2006.
Women comprised 55% of the study cohort (Table 1). The
median age was 35 years (range, 21–57 years) among men and 34
years (range, 18–61 years) among women (p=0.14). Most patients
had a Karnofsky score $70% at the time of KS diagnosis (78%),
and 65 (33%) were considered underweight with a BMI of less
than 18.5 kg/m
2; Karnofsky score and BMI did not differ
significantly between men and women. Among the 153 (78%)
patients with a CD4 T-cell count documented within 6 months of
KS diagnosis, the median CD4 count was 84 cells/mm
3 (IQR:
14–208 cells/mm
3). The CD4 count was significantly lower in
women (median 58 cells/mm
3; IQR: 11–156 cells/mm
3) than
men (median 124 cells/mm
3; IQR: 22–254 cells/mm
3) (p=0.02).
KS Clinical Presentation
KS diagnosis was confirmed by histology in 123 (62%) of the
patients; the rest of the cases were diagnosed clinically. Sixty-six
(34%) patients were classified as T0 tumor stage and 116 (59%)
were classified as T1 at KS diagnosis. Tumor stage did not differ
significantly between men and women.
Lesions involved the following locations among patients at KS
presentation: 47 (24%) face or neck; 69 (35%) hard palate; 30
(15%) oral cavity outside hard palate; 43 (22%) trunk; 43 (22%)
upper extremities; 125 (63%) lower extremities; 11 (6%) genitals.
Ninety-seven (49%) patients had KS lesions involving 2 or more
anatomic locations. The median number of lesions per patient was
7 (range, 1–85 lesions).
Women were more likely than men to present with lesions
involving the face or neck (OR 2.8, 95% CI, 1.4, 5.7; p=0.005)
and hard palate (OR 2.0, 95% CI, 1.1, 3.7; p=0.02). Women
were less likely than men to have lower extremity lesions (OR 0.54,
95% CI, 0.30, 0.99; p=0.05) (Figure 1). The greater likelihood of
lesions involving the face or neck among women remained
significant after adjusting for CD4 count. There were no gender
differences in the number of involved anatomic locations or the
total number of lesions at presentation.
Fifty-one (26%) patients had macular lesions, 42 (21%) had
nodular lesions, 10 (5%) had fungating lesions, and 98 (50%) did
not have lesion morphotype documented (Figure 2). Only 7 (3%)
had more than one type of lesion. Women were less likely than
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Characteristic Total Cohort (N=197) Men (N=89) Women (N=108) P-value
1
Age at KS Diagnosis (median, range) 35 (18, 61) 35 (21–57) 34 (18–61) 0.18
BMI:
Underweight (,18.5 kg/m
2) 65 (33%) 25 (28%) 40 (37%) 0.30
Normal weight ($18.5 kg/m
2) 97 (49%) 45 (51%) 52 (48%)
Missing 35 (18%) 19 (21%) 16 (15%)
Karnofsky Score:
,70 30 (15%) 14 (16%) 16 (15%) 0.85
$70 154 (78%) 69 (77%) 85 (79%)
Missing 13 (7%) 6 (7%) 7 (6%)
Baseline CD4 Count (n=153)
2
(,6 mos of KS dx), Median (IQR)
84 (14, 208) 124 (22,254) 58 (11, 156) 0.01
Tumor Stage:
T0 66 (34%) 29 (33%) 37 (34%) 0.50
T1 116 (59%) 57 (64%) 59 (55%)
Not specified 15 (7%) 3 (3%) 12 (11%)
Number of Locations Involved
1 81 (41%) 41 (46%) 40 (37%) 0.40
2 or more 97 (49%) 43 (48%) 54 (50%)
Missing 19 (10%) 5 (6%) 14 (13%)
Number of Lesions
,10 68 (35%) 32 (36%) 36 (33%) 0.77
$10 43 (22%) 19 (21%) 24 (22%)
Missing 86 (44%) 38 (43%) 48 (44%)
Lesion-associated Edema
Edema 67 (34%) 41 (46%) 26 (24%) 0.002
No edema 127 (65%) 48 (54%) 79 (73%)
Missing 3 (1%) 0 (0%) 3 (3%)
1P-values reflect presence of characteristic in men vs. women, calculated using logistic regression. Calculations exclude ‘‘Missing’’ or ‘‘Not Specified’’ data. P-value for
lesion type and location reflect presence of listed characteristic in men vs women.
2N=153 (78%) with CD4 documented within 6 months of KS diagnosis.
doi:10.1371/journal.pone.0013936.t001
Figure 1. Location of KS Lesions By Gender. Women were more likely than men to have KS lesions involving the face (32% vs 15%, p=0.005)
and the hard palate (43% vs 27%, p=0.02). Women were less likely than men to have lower extremity lesions (58% vs 72%, p=0.05).
doi:10.1371/journal.pone.0013936.g001
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p=0.003), which remained significant after adjusting for CD4
count and lesion location.
Edema was associated with KS lesions in 67 (34%) patients.
Women were less likely than men to have edema at any location
(OR 0.38, 95% CI, 0.21, 0.71; p=0.002). This difference was
attenuated slightly after adjusting for CD4 count and lower
extremity involvement (OR 0.45, 95% CI, 0.19, 1.05; p=0.06).
Clinical Response
177 (90%) of 197 patients had at least 1 follow-up visit after
diagnosis of KS, of whom 84 (47%) were men and 93 (53%) were
women. During the 6-month period of follow up, 68 (38%) of the
177 patients had improvement in KS disease. The 6-month
cumulative incidenceof improvement was 0.50(95% CI0.41, 0.58).
Women were less likely to demonstrate clinical improvement
than men (Figure 3). This finding was near statistical significance
in univariate analysis (HR=0.64, CI 0.40, 1.04; p=0.07) and
significant in multivariate analysis, with women having a 0.52 fold
decreased probability of clinical improvement compared to men
(CI 0.31, 0.88; p=0.01). Presenting with lesions located on the
hard palate was associated with a 2.0 fold greater probability of
improvement (CI 1.2, 3.4; p=0.008) and on the trunk with a 1.7
fold greater probability of improvement (CI 1.0, 2.8; p=0.04) in
the multivariate model.
No other variables, including age, BMI, Karnofsky score,
baseline CD4 count, tumor stage, lesion location, number of
lesions, or presence of edema were found to be associated with
likelihood of improvement in multivariate analysis.
Discussion
Our study found that both the clinical presentation of KS and
clinical outcomes differ between men and women in Uganda.
Women presented with lower CD4 T-cell counts at diagnosis, had
frequent orofacial KS, and were less likely to have tumor-
associated edema or nodular lesions than men. Women were also
less likely to demonstrate clinical improvement than men.
Women in our study had significantly lower CD4 counts at KS
diagnosis than men, as has been reported by others [8,9]. The
frequency of this finding across several studies suggests that greater
immunosuppression may be an intrinsic part of the pathophysi-
ology of KS in women. More severe immunosuppression due to
HIV may be needed in women for KS to overcome gender-related
factors, including hormonal, environmental, or genetic factors,
which normally protect women against the disease. Human
chorionic gonadotrophin (hCG) has been hypothesized to be a
protective factor in KS development based on its inhibition of the
growth KS cell lines in vitro [18]. However, therapeutic trials of
intralesional hCG have been inconclusive and pregnancy does not
affect the risk of developing KS, suggesting factors other than hCG
are important [19–21]. Gender-based differences in immune
responses, as evidenced epidemiologically by differences in rates of
autoimmune disease or vaccine response in men and women [22],
could also contribute to differences in KS presentation and
response. Control of HHV-8, the etiologic agent of KS, may also
differ in men and women, as evidenced by a cohort study of
persons with HIV and KS in Uganda showing that men have
higher rates of HHV-8 replication in mucosa and peripheral blood
than women [23]. HHV-8 replication is in turn an essential step in
the development of KS [24–28]. However, in US [29,30] and
Ugandan [31] cohorts, lower CD4 counts were not associated with
poorer control of HHV-8 replication. Thus the interaction
between immunosuppression, HHV-8 replication and develop-
ment of KS in women needs to be further investigated.
Figure 2. Types of KS Lesions By Gender. Women were significantly less likely to present with nodular KS lesions compared to men (13% vs 31%,
p=0.003), (N=99).
doi:10.1371/journal.pone.0013936.g002
Figure 3. Cumulative Incidence of Improvement By Gender.
Univariate analysis (HR=0.64, CI 0.40, 1.04; p=0.07).
doi:10.1371/journal.pone.0013936.g003
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between men and women. Our finding that women had frequent
oral KS lesions is in agreement with previous studies [9]. Notably,
the presence of lesions on the hard palate was also associated with
a greater hazard of improvement. It is unclear why palatal lesions
would be associated with improvement, particularly since palatal
KS has been identified as a marker of pulmonary KS in Uganda
[32]. It is possible that persons with more severe disease offer a
greater opportunity for clinicians to observe a clinical response,
though we did not find an association between burden of disease as
measured by number of lesions or lesion locations and response.
The trend that men are more likely to present with lower
extremity lesions and associated edema mirrors the typical
presentation of non-HIV-associated KS, which is predominantly
a disease of men. The higher likelihood of lower extremity
involvement in men supports the notion that there may be gender
differences in KS pathophysiology.
Male gender was significantly associated with the probability of
clinical improvement. Importantly, this association remained after
adjusting for KS clinical presentation, suggesting that the lower
likelihood of clinical improvement in women may in part be
attributed to additional factors beyond the more severe disease
presentation and greater immunosuppression at KS diagnosis
observed among women in our cohort. Of note, we did not
identify any cases of KS immune reconstitution inflammatory
syndrome (IRIS) in our cohort, and we are not aware of gender
differences in IRIS risk that could account for the lower rate of KS
improvement in women. A factor not evaluated in our study that
could impact our findings is the type of therapy received by men
and women. KS treatment usually involves administration of
antiretroviral therapy and chemotherapy, but the treatment
provided to men and women in our cohort may have differed
due to clinical or socioeconomic factors. However, if the pathology
of KS differs in men and women, it is also possible that equivalent
KS treatment regimens are not equally effective in women. Future
studies of KS in women should include evaluation of treatment to
measure the effect of treatment on response and to determine if
current therapies are equally efficacious in both genders.
Health care utilization and health-seeking behaviors may have
also differed among men and women. For example, men may have
been more likely to have money to pay for chemotherapy than
women, perhaps contributing to the higher rate of clinical
improvement we observed in men. Additionally, women tend to
have greater exposure to HIV testing as routine counseling and
testing has been applied to perinatal settings, and this may have
allowed for both a greater number of KS cases and perhaps earlier
stage disease to be identified among women. The frequency of
clinic attendance after KS diagnosis could also influence the
likelihood of receiving treatment or observing an ‘‘improved’’
response, but we found no difference in follow-up time between
men and women in our cohort. Future prospective studies should
also capture detailed data on health care utilization patterns to
carefully evaluate their impact on KS outcomes in men and
women.
Our study has several important limitations. As a retrospective
chart review, our study is subject to incomplete data which may
have led to misclassification of presentation or response variables,
and consequently limited our ability to observe important
associations. In particular, complete ACTG staging was not
available for patients and there was limited assessment of visceral
KS involvement in this cohort. Our classification of ‘‘improve-
ment’’ relied on clinician documentation in charts, and it is
possible that changes in lesion size, lesion number, or edema were
not consistently documented in the medical record. Underesti-
mating ‘‘improvement’’ should lead to a conservative misclassifi-
cation, however, and would diminish the apparent difference in
clinical improvement between men and women. Further, we could
not reliably determine other important outcome measures, in-
cluding mortality, because we were unable to ascertain if loss to
follow up was due to death or another factor. Clinical impro-
vement as defined by any lesion regression may not corres-
pond to survival benefit, so it will be important to evaluate survival
in future studies.
Despite these limitations, our study supports the hypothesis that
gender affects the pathophysiology of HIV-associated KS. Our
findings suggest that it may be possible to prevent many cases of
KS in HIV-infected women if they are able to initiate ART at
higher CD4 T-cell counts, as recommended by international
guidelines [33], and that clinicians caring for HIV-infected women
in KS-endemic areas should carefully examine the hard palate for
earlier detection of KS. Prospective studies are needed to identify
predictors of response and to evaluate response to treatment in
women with KS, particularly in Africa where the disease burden is
greatest. Such studies will not only address potential gender
disparities in KS management, but will also provide an
unprecedented opportunity to gain insight into the basic
pathophysiology of KS by exploring gender differences in a
disease that, prior to the AIDS epidemic, was almost exclusively
found in men.
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